8 News & Press Releases found

IceCure Medical Ltd news

Icecure medical presents Ice3 breast cancer trial interim data, hosts cryoablation symposium & conducts hands-on Prosense Training Sessions at the European Conference on Interventional Oncology

IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) (“IceCure” or the “Company”), developer of minimally-invasive cryoablation technology, the ProSense System, that destroys tumors by freezing as an alternative to surgical tumor removal, today announced it hosted three key ProSense System

Apr. 2, 2022

Icecure medical ltd. Closes $17 million underwritten public offering and partial exercise of over-allotment option

IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM.TA) (the “Company” or “IceCure”), developer of minimally-invasive cryoablation technology, the ProSense^® System, that destroys tumors by freezing as an alternative to surgical tumor removal, today announced the closing of its underwritten public offering of 3,892,152 shares of the Company’s ordinary shares, inclusive of 578,325 shares offered pursuant to the unde

Dec. 0, 2021

Icecure Medical enters into an exclusive agreement in Poland for distribution of the Prosense Cryoablation System

IceCure Medical Ltd. (Nasdaq: ICCM) (TASE: ICCM) (“IceCure” or the “Company”), developer of the next generation minimally invasive cryoablation technology that destroys tumors by freezing, today announced that it has entered into an initial distribution agreement with Mobile SCANMED Systems SP. z o.o. (“Mobile SCANMED Systems”) to exclusively sell the Company’s ProSense™ Cryoablation System and disposables in Poland. Within twelve months of sign

Oct. 2, 2021

Icecure Medical announces updated regulatory strategy in china for the icesense3 system to treat Cancerous Tumors with Cryoablation

IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) (“IceCure” or the “Company”), developer of the next generation minimally invasive cryoablation technology that destroys tumors by freezing, today announced the advancement of its regulatory strategy in China with the submission of an amendment to the registration certificate for the IceSense3^® system, which was granted by China’s National Medical Products Administration (“NMPA

Oct. 1, 2021

Icecure Medical announces new independent data published in the journal of cancer therapy showing that percutaneous Cryoablation presents a potential substitute for lumpectomy for tumors <15mm using Prosense

IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) (“IceCure” or the “Company”), developer of the next generation minimally invasive cryoablation technology that destroys tumors by freezing, today announced that a peer reviewed article titled, “VAB and MRI Following Percutaneous Ultra-Sound Guided Cryoablation for Primary Early-Stage Breast Cancer: A Pilot Study in Japan,” was published in the Journal of Cancer Therapy by lead author Dr. Hisanori Kawamo

Oct. 0, 2021